162 related articles for article (PubMed ID: 35872799)
1. Bone Specific Alkaline Phosphatase and Serum Calcification Propensity Are Not Influenced by Etelcalcetide vs. Alfacalcidol Treatment, and Only Bone Specific Alkaline Phosphatase Is Correlated With Fibroblast Growth Factor 23: Sub-Analysis Results of the ETACAR-HD Study.
Dörr K; Hödlmoser S; Kammer M; Reindl-Schwaighofer R; Lorenz M; Reiskopf B; Jagoditsch R; Marculescu R; Oberbauer R
Front Med (Lausanne); 2022; 9():948177. PubMed ID: 35872799
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Shoji T; Nakatani S; Kabata D; Mori K; Shintani A; Yoshida H; Takahashi K; Ota K; Fujii H; Ueda S; Nishi S; Nakatani T; Yoshiyama M; Goto K; Hamada T; Imanishi M; Ishimura E; Kagitani S; Kato Y; Kumeda Y; Maekawa K; Matsumura T; Nagayama H; Obi Y; Ohno Y; Sai Y; Sakurai M; Sasaki S; Shidara K; Shoji S; Tsujimoto Y; Yamakawa K; Yasuda H; Yodoi S; Inaba M; Emoto M
Clin J Am Soc Nephrol; 2021 Apr; 16(4):599-612. PubMed ID: 33685864
[TBL] [Abstract][Full Text] [Related]
3. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T
Clin Ther; 2018 Dec; 40(12):2099-2111. PubMed ID: 30473399
[TBL] [Abstract][Full Text] [Related]
4. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).
Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Loewe C; Marculescu R; Erben R; Oberbauer R
Trials; 2019 Oct; 20(1):601. PubMed ID: 31651370
[TBL] [Abstract][Full Text] [Related]
5. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis.
Wolf M; Block GA; Chertow GM; Cooper K; Fouqueray B; Moe SM; Sun Y; Tomlin H; Vervloet M; Oberbauer R
Clin Kidney J; 2020 Feb; 13(1):75-84. PubMed ID: 32082556
[TBL] [Abstract][Full Text] [Related]
6. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity.
Grethen E; Hill KM; Jones R; Cacucci BM; Gupta CE; Acton A; Considine RV; Peacock M
J Clin Endocrinol Metab; 2012 May; 97(5):1655-62. PubMed ID: 22362819
[TBL] [Abstract][Full Text] [Related]
7. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.
Yu L; Tomlinson JE; Alexander ST; Hensley K; Han CY; Dwyer D; Stolina M; Dean C; Goodman WG; Richards WG; Li X
Calcif Tissue Int; 2017 Dec; 101(6):641-653. PubMed ID: 29038882
[TBL] [Abstract][Full Text] [Related]
8. High-Flux Hemodialysis and High-Volume Hemodiafiltration Improve Serum Calcification Propensity.
Dekker M; Pasch A; van der Sande F; Konings C; Bachtler M; Dionisi M; Meier M; Kooman J; Canaud B
PLoS One; 2016; 11(4):e0151508. PubMed ID: 27064679
[TBL] [Abstract][Full Text] [Related]
9. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial.
Bressendorff I; Hansen D; Schou M; Pasch A; Brandi L
Clin J Am Soc Nephrol; 2018 Sep; 13(9):1373-1380. PubMed ID: 30131425
[TBL] [Abstract][Full Text] [Related]
11. The effect of parathyroid hormone lowering by etelcalcetide therapy on calcification propensity and calciprotein particles in hemodialysis patients.
Thiem U; Lenz J; Haller MC; Pasch A; Smith ER; Cejka D
Clin Kidney J; 2024 Jun; 17(6):sfae097. PubMed ID: 38919277
[TBL] [Abstract][Full Text] [Related]
12. Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review.
Pluquet M; Kamel S; Choukroun G; Liabeuf S; Laville SM
Toxins (Basel); 2022 Sep; 14(9):. PubMed ID: 36136575
[TBL] [Abstract][Full Text] [Related]
13. Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial.
Bristow SM; Gamble GD; Pasch A; O'Neill WC; Stewart A; Horne AM; Reid IR
Osteoporos Int; 2016 Mar; 27(3):1209-1216. PubMed ID: 26493812
[TBL] [Abstract][Full Text] [Related]
14. Phosphocalcic Markers and Calcification Propensity for Assessment of Interstitial Fibrosis and Vascular Lesions in Kidney Allograft Recipients.
Berchtold L; Ponte B; Moll S; Hadaya K; Seyde O; Bachtler M; Vallée JP; Martin PY; Pasch A; de Seigneux S
PLoS One; 2016; 11(12):e0167929. PubMed ID: 28036331
[TBL] [Abstract][Full Text] [Related]
15. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
[TBL] [Abstract][Full Text] [Related]
16. Serum calcification propensity and its association with biochemical parameters and bone mineral density in hemodialysis patients.
Kim H; Kim AJ; Ro H; Chang JH; Lee HH; Chung W; Jung JY
Kidney Res Clin Pract; 2023 Mar; 42(2):262-271. PubMed ID: 36328988
[TBL] [Abstract][Full Text] [Related]
17. The effect of six-month oral vitamin K supplementation on calcification propensity time in individuals with type 2 diabetes mellitus: A post hoc analysis of a randomized, double-blind, placebo-controlled trial.
Meer R; Romero Prats ML; Vervloet MG; van der Schouw YT; de Jong PA; Beulens JWJ
Atherosclerosis; 2024 Jul; 394():117307. PubMed ID: 37852868
[TBL] [Abstract][Full Text] [Related]
18. Serum Calcification Propensity T50 Is Associated with Soluble Thrombomodulin in Patients on Hemodialysis.
Tadokoro T; Kato A; Ohmori H; Matsumoto T; Kuro-O M; Kobayashi T; Ohdan H
J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930020
[No Abstract] [Full Text] [Related]
19. New Markers of Bone Fragility in Hemodialysis Patients: A Monocentric Study.
Slouma M; Aissaoui T; Abbes M; Bahlous A; Laadhar L; Smaoui W; Gharsallah I; Ben Moussa F; Elleuch M; Sahli H; Cheour E
J Clin Densitom; 2021; 24(1):22-27. PubMed ID: 33288423
[TBL] [Abstract][Full Text] [Related]
20. ITGAM rs1143679 Variant in Systemic Lupus Erythematosus Is Associated with Increased Serum Calcification Propensity.
Halfon M; Zhang L; Ehirchiou D; Pandian VD; Dahdal S; Huynh-Do U; Pasch A; Ribi C; Busso N
Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
